Z-338 (Zeria/Yamanouchi)

Current Opinion in Investigational Drugs

Volumn 5, Issue 7, 2004, Pages 760-765

  Lehmann, Anders ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE DERIVATIVE; CHOLINESTERASE INHIBITOR; GASTROINTESTINAL AGENT; HYPNOTIC SEDATIVE AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; N [2 (DIISOPROPYLAMINO)ETHYL] 2 (2 HYDROXY 4,5 DIMETHOXYBENZAMIDO) 4 THIAZOLECARBOXAMIDE; NEW DRUG; THIAZOLE DERIVATIVE;

ANIMAL; ARTICLE; BIOAVAILABILITY; CHEMICAL STRUCTURE; DOG; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG INDUSTRY; DRUG SCREENING; DYSPEPSIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; GUINEA PIG; HUMAN; METABOLISM; METHODOLOGY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; RAT; SWEDEN; SYNTHESIS; XENOPUS;

ANIMALS; BENZAMIDES; BIOLOGICAL AVAILABILITY; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS, PHASE II; DOGS; DRUG ADMINISTRATION ROUTES; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; DYSPEPSIA; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; GUINEA PIGS; HUMANS; HYPNOTICS AND SEDATIVES; MOLECULAR STRUCTURE; MULTICENTER STUDIES; RATS; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M2; SWEDEN; THIAZOLES; XENOPUS;

EID: 5044241923     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. 105509 Cisapride stimulates motility of the intestine via the 5-hydroxytryptamine receptors. Taniyama L, Nakayama S, Takeda K, Matsuyama S, Shirakawa J, Sano I, Tanaka C J PHARMACOL EXP THER 1991 258 3 1098-1104
2. 285836 In vitro pharmacological profiles of Z-338, a novel prokinetic agent. Ueki S, Yoshida K, Eta R, Tochigi M, Yoneta T, Kurimoto T, Itoh Z, Ogishima M, Taniyama K JPN J PHARMACOL 1998 76 Suppl 1 Abs P-630
3. 300072 Z-388, a novel prokinetic agent, stimulates gastrointestinal motor activity and improves delayed gastric emptying in the dog and rat. Ueki S, Matsunaga Y, Matsumura T, Hori Y, Yoneta T Kurimoto T Tamaki H Itoh Z NAUNYN SCHMIEDEBERGS ARCH PHARMACOL 1998 358 Suppl 1 No 1 P40.14
4. 300533 In vitro pharmacological profiles of Z-388, a novel gastro prokinetic agent. Kurimoto T, Yoshida K, Eta R, Tochigi M, Sato R, Yoneta T, Tamaki Z, Itoh Z, Ogishima M, Taniyama K NAUNYN SCHMIEDEBERGS ARCH PHARMACOL 1998 358 Suppl 1 No 1 P40.33
5. 4 receptors. Ueki S, Matsunga Y, Yoshida K, Yoneta T, Kurimoto T, Itoh Z GASTROENTEROLOGY 1999 117 Abs 2513
6. 348884 Zeria plans clinical studies on Ancer to treat HIV infection in US. PHARMA JPN 1999 1674 4
7. 365090 The effect of Z-338, a new gastroprokinetic agent, on the isolated segment of the opossum lower esophageal sphincter. Kurimoto T, Mashimo H, Goyal RK JPN J PHARMACOL 2000 82 Suppl 1 P-544
8. 366946 The effect of Z-338, a new gastroprokinetic agent, on the isolated segment of the opossum lower esophageal sphincter. Kurimoto T, Mashimno H, Goyal RK GASTROENTEROLOGY 2000 118 4 Suppl 2 Abs 3213
9. 368568 Infergen (Interferon alfacon-1). Amgen Inc COMPANY BROCHURE 2000 November 30
10. 376896 Z-338: Phase I, single and multiple oral dose, safety, tolerability and pharmacokinetic studies in healthy male subjects. Oliver SD, Ward C, Ward J, Kato H, Saito Y, Furuta S BR J CLIN PHARMACOL 2000 Abs 948
11. 377656 AstraZeneca R&D pipeline: NCEs. AstraZeneca plc COMPANY WORLD WIDE WEB SITE 2000 August 01
12. 393175 Zeria: Ethical drug sales up 4% in first half. PHARMA JPN 2000 1724 15
13. 405131 Zeria aims at 80 billion yen sales net profit ratio of 10% in 2005. PHARMA JPN 2001 1741 5-6
14. 407394 Z-338 potentially antagonizes muscarinic M1 and M2 receptors expressed in Xenopus oocytes. Murasaki O, Taniyama K, Kaibara M, Uezono Y, Nagase Y, Doi Y, Zhang S JPN J PHARMACOL 2001 85 Suppl 1 P-218
15. 407379 Z-338 enhances acetylcholine release from the canine stomach by blocking muscarinic autoreceptors in vivo microdalysis. Ueki S, Ogishima M, Higashino R, Yoneta T, Kurimoto T Kaibara M, Taniyama K JPN J PHARMACOL 2001 85 Suppl 1 P-186
16. 411858 Z-338 enhances acetylcholine release from the canine stomach in vivo microdialysis by blocking muscarinic autoreceptors. Ueki S, Ogishima M, Higashino R, Yoneta T, Kurimoto T, Kaibara M, Taniyama K, Itoh Z GASTROENTEROLOGY 2001 120 5 Suppl 1 A289
17. 457188 Zeria and Yamanouchi sign letter of intent for development and marketing of the gastroprokinetic Z-338. Yamanouchi Pharmaceutical Co Ltd PRESS RELEASE 2002 July 01
18. 463776 Zelnorm now available in US Pharmacies. Novartis AG PRESS RELEASE 2002 September 13
19. 472250 Aiming at no 1 position in urology in Europe: Mr Takenaka of Yamanouchi. PHARMA JPN 2002 1821 1-3
20. 509345 An electrophysiological study of muscarinic and nicotinic receptors of rat paratracheal ganglion neurons and their inhibition by Z-338. Kanemoto Y, Ishibashi H, Doi A, Akaike N, Ito Y BR J PHARMACOL 2002 135 6 1403-1414
21. 2+ currents in guinea pig stomach. Morita H, Abe K, Ito Y, Inoue R JPN J PHARMACOL 2002 89 4 356-365
22. 509349 A phase II randomised multicentric double-blind placebo controlled parallel group pilot study with Z-338 in functional dyspepsia (FD) patients. Tack J, Masclee A, Headin R, Berstad A, Piessevaux H, Popiela T, Vandenberghe A, Kobayashi S GUT 2002 51 3 A42
23. 509350 LC determination of Z-338, novel gastroprokinetic agent in dog plasma by SCX solid phase extraction. Furuta S, Miyahara H, Sugimoto T, Sano H J PHARM BIOMED ANAL 2001 25 3-4 599-603
24. 509356 Z-338, a newly synthetized carboxyamide derivative, stimulates gastric motility through enhancing the excitatory neurotransmission. Nakajima T, Nawata H, Ito Y J SMOOTH MUSCLE RES 2000 36 2 69-81
25. 509357 Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach. Ogishima M, Kaibara M, Uek S, Kurimoto T, Taniyama K J PHARMACOL EXP THER 2000 294 1 33-37
26. 513914 Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. McCallum RW, Prakash C, Campoli-Richards DM, Goa KL DRUGS 1988 36 6 652-681
27. 514000 Gastric electrical stimulation for medically refractory gastroparesis. Abell T, McCallum R, Hocking M, Koch K, Abrahamsson H, Leblanc I, Lindberg G, Konturek J, Nowak T, Quigley EM, Tougas G et al GASTROENTEROLOGY 2003 125 2 421-428
28. 514009 Effect of atropine on proximal gastric motor and sensory function in normal subjects. Lidums I, Hebbard GS, Holloway RH GUT 2000 47 1 30-36
29. 514029 Proximal gastric tone in gastro-oesophageal reflux disease. Zerbib F, des Varannes SB, Ropert A, Lamouliatte H, Quinton A, Galmiche JP EUR J GASTROENTEROL HEPATOL 1999 11 5 511-515
30. 514035 Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. van Herwaarden MA, Samsom M, Smout AJ GASTROENTEROLOGY 2000 119 6 1439-1446
31. 514044 Causes and treatment of functional dyspepsia. Tack J, Bisschops R, DeMarchi B CURRENT GASTROENTEROLOGY REPORTS 2001 3 6 503-508
32. 518205 Review article: Promotility drugs in the treatment of gastro-oesophageal reflux disease. Ramirez B, Richter JE ALIMENT PHARMACOL THER 1993 7 1 5-20
33. 540996 Muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea-pig. Fryer AD, Maclagan J BR J PHARMACOL 2004 83 4 973-978
34. 540997 Prejunctional inhibitory muscarinic receptors on cholinergic nerves in human and guinea pig airways. Minette PA, Barnes PJ J APPL PHYSIOL 1988 64 6 2532-2537
35. 541012 Prejunctional muscarinic receptors regulating neurotransmitter release in airways. Kilbinger H, von Bardeleben RS, Siefken H, Wolf D LIFE SCI 1995 56 11-12 981-987
36. 541015 Autoregulation of acetylcholine release from vagus nerve terminals through activation of muscarinic receptors in the dog trachea. Ito Y, Yoshitomi T BR J PHARMACOL 1988 93 3 636-646
37. 541018 Origin and modulation of ACh release from rat airway cholinergic nerves. Zhu FX, Zhang XY, Robinson NE AM J PHYSIOL 1997 272 1 1 L8
38. 541020 Long QT syndrome during high-dose cisapride. Bran S, Murray WA, Hirsch IB, Palmer JP ARCH INTERN MED 1995 155 7 765-768
39. 541518 Analyst evaluation of Yamanouchi Pharmaceutical Co Ltd. Sakai F DEUTSCHE BANK AG 2004 March 23